Last reviewed · How we verify
Test Vaccine Vi-DT Typhoid conjugate
Vi-DT Typhoid conjugate vaccine stimulates the immune system to produce antibodies against Salmonella Typhi.
Vi-DT Typhoid conjugate vaccine stimulates the immune system to produce antibodies against Salmonella Typhi. Used for Prevention of typhoid fever.
At a glance
| Generic name | Test Vaccine Vi-DT Typhoid conjugate |
|---|---|
| Also known as | Vi-DT Typhoid conjugate vaccine |
| Sponsor | International Vaccine Institute |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing a weakened form of the Salmonella Typhi bacteria, which triggers an immune response and helps the body produce antibodies to fight the infection. These antibodies provide long-term protection against typhoid fever.
Approved indications
- Prevention of typhoid fever
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh (PHASE1, PHASE2)
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine (PHASE1)
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: